74 related articles for article (PubMed ID: 24462470)
1. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.
Picchio G; De Meyer S; Dierynck I; Ghys A; Gritz L; Kieffer TL; Bartels DJ; Witek J; Bengtsson L; Luo D; Kauffman RS; Adda N; Sarrazin C
J Clin Virol; 2014 Mar; 59(3):148-55. PubMed ID: 24462470
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
[TBL] [Abstract][Full Text] [Related]
3. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Nakamuta M; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
Antiviral Res; 2014 Apr; 104():102-9. PubMed ID: 24462955
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Harrington PR; Zeng W; Naeger LK
Hepatology; 2012 Apr; 55(4):1048-57. PubMed ID: 22095516
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
6. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C.
Vermehren J; Yu ML; Monto A; Yao JD; Anderson C; Bertuzis R; Schneider G; Sarrazin C
J Clin Virol; 2011 Oct; 52(2):133-7. PubMed ID: 21803650
[TBL] [Abstract][Full Text] [Related]
7. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
[TBL] [Abstract][Full Text] [Related]
9. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
10. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
Dumortier J; Guillaud O; Gagnieu MC; Janbon B; Juillard L; Morelon E; Leroy V
J Clin Virol; 2013 Feb; 56(2):146-9. PubMed ID: 23149155
[TBL] [Abstract][Full Text] [Related]
11. Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients.
Crawford DH; Dore GJ; Sievert W; Cheng WS; Weltman M; McCaughan G; Rawlinson W; Marks PS; Yoshihara M; Rizkalla B; Roberts SK;
Antivir Ther; 2012; 17(5):849-54. PubMed ID: 22513456
[TBL] [Abstract][Full Text] [Related]
12. [The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients].
Ma L; Zhao H; Xie Y; Li MH; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):565-8. PubMed ID: 16938164
[TBL] [Abstract][Full Text] [Related]
13. Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
De Meyer S; Ghys A; Dierynck I; Beumont M; Luo D; Picchio G
Virol J; 2014 May; 11():93. PubMed ID: 24886541
[TBL] [Abstract][Full Text] [Related]
14. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis.
De Nicola S; Aghemo A; Campise MR; D'Ambrosio R; Rumi MG; Messa P; Colombo M
Antivir Ther; 2014; 19(5):527-31. PubMed ID: 24009104
[TBL] [Abstract][Full Text] [Related]
17. HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
Lange CM; Susser S; Herrmann E; Karey U; Kieffer TL; Kwong AD; Schinkel J; Reesink HW; Zeuzem S; Sarrazin C
Scand J Gastroenterol; 2011 Nov; 46(11):1362-8. PubMed ID: 21815864
[TBL] [Abstract][Full Text] [Related]
18. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
Sarrazin C; Dierynck I; Cloherty G; Ghys A; Janssen K; Luo D; Witek J; Buti M; Picchio G; De Meyer S
J Clin Microbiol; 2015 Apr; 53(4):1264-9. PubMed ID: 25653396
[TBL] [Abstract][Full Text] [Related]
19. Modeling viral evolutionary dynamics after telaprevir-based treatment.
Haseltine EL; De Meyer S; Dierynck I; Bartels DJ; Ghys A; Davis A; Zhang EZ; Tigges AM; Spanks J; Picchio G; Kieffer TL; Sullivan JC
PLoS Comput Biol; 2014 Aug; 10(8):e1003772. PubMed ID: 25101970
[TBL] [Abstract][Full Text] [Related]
20. Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis.
Cindoruk M; Karakan T; Unal S
Curr Ther Res Clin Exp; 2005 Sep; 66(5):451-62. PubMed ID: 24790245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
